Dewpoint Therapeutics’ Post

📉 In this multicenter, randomized, double-blind, placebo-controlled, two-by-two factorial trial conducted in China, patients with acute Mild Ischemic Stroke or High-risk TIA of presumed atherosclerotic origin who received combined CLOPIDOGREL and ASPIRIN within 72 hours after symptom onset had a risk of stroke at 90 days that was approximately 2 percentage points lower than the risk with aspirin alone. 📈 The risk of moderate-to-severe bleeding was approximately twice as high in the clopidogrel–aspirin group as in the aspirin group, although this risk was low in both groups.

#genetherapy has the potential to revolutionize the way we treat many rare diseases. Hear the scientific, biosafety, clinical trial, and clinical care perspectives on this growing concern in Advarra's January 18 webinar.  #clinicalresearch #clinicaltrials #lifesciences

#genetherapy has the potential to revolutionize the way we treat many rare diseases. Hear the scientific, biosafety, clinical trial, and clinical care perspectives on this growing concern in Advarra's January 18 webinar.  #lifesciences #clinicalresearch #clinicaltrials

Having the right and enough #biospecimens for your research is often a challenge. Our disease-state leukopaks provide billions of cells from a single donor. ✔️ Fresh or cryopreserved ✔️ 30+ diagnosed conditions including SLE , #rheumatoidarthritis, #multiplesclerosis, and Myasthenia Gravis ✔️ Comprehensive donor data Explore how you can accelerate your therapeutic development: https://lnkd.in/dyWYKgFC #celltherapy #genetherapy #sanguineleukopaks

Take a look at the re-vamped fibrosis page on PhenoVista's website here! https://hubs.ly/Q02sYTf20 There's a general overview of our capabilities in this disease area and a case study of a completed client project. If you don't find what you're looking for or want to discuss challenges you're facing in fibrosis R&D, shoot let's chat!

🔬Did you know? During Stroke Awareness Month, we're highlighting groundbreaking research! The CHANCE-2 study found that treating minor stroke/transient ischemic attack patients carrying one or two CYP2C19 loss-of-function alleles with aspirin plus ticagrelor lowered their risk of a second stroke at 90 days more effectively than aspirin plus clopidogrel. (1) This emphasizes the critical role of early identification of a minor stroke or TIA patient's CYP2C19 genotype to optimize DAPT. (1) Let's spread awareness and advocate for genotype-guided DAPT to help prevent recurrent strokes! 🧬 #StrokeAwareness #Pharmacogenetics #StrokePrevention #OptimizedDAPT #PrecisionMedicine 1. Wang Y, Meng X, Wang A, et al. Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. N Engl J Med. 2021;385(27):2520-2530. doi:10.1056/NEJMoa2111749

March 2024 marks The Journal of Critical Limb Ischemia's three-year anniversary! Journal of Critical Limb Ischemia is the only peer-reviewed journal dedicated to advancing the treatment of critical limb-threatening ischemia. The goal of the journal is to provide an international forum for the presentation of original ideas and recent results related to all aspects of diagnostic, therapeutic and pathophysiologic aspects of critical limb ischemia. Journal of Critical Limb Ischemia is the official journal of the CLI Global Society. JCLI is the first and only academic journal to focus on interventional techniques pertaining to the complex disease. Learn more >> clijournal.com #CLIFighters

#Preclinical researchers in #IPF ( Idiopathic Pulmonary Fibrosis ) >> By reducing the mortality rate from an industry average of 40% to 20%, while maintaining significant and reproducible results, our IPF disease model provides valuable insights to biopharm and biotech companies far more quickly, saving valuable therapeutic discovery and development time and money. Learn more >> https://lnkd.in/gsBchHBF #MLMAdvantage #diseasemodels #preclinicalresearch

SHIP-CT study is a major milestone clearly demonstrating that imaging-based quantification can precisely assess treatment efficacy. The study was conducted in children with cystic fibrosis, using chest CT as the primary outcome measure. This external validation proves the specificity and high-precision sensitivity of LungQ™ Bronchus-Artery (BA) for an objective quantification of bronchial wall thickening and bronchial widening, as well as its importance for the assessment of a treatment effect. Read the full publication: https://lnkd.in/eQ-7iaq5

We asked Luisa Avedano (EFCCA Chief Executive Officer) three questions. 1.     What is your motivation to participatie in the METHYLOMIC project? 2.     What do you think is the biggest challenge in this project? 3.     What do you hope this research will bring to the lives of patients with Crohn’s disease? Luisa: “Our main motivation is to be part of cutting-edge research aimed at advancing the understanding of the disease and in particular predicting the response of some specific biological treatments, that can lead to the development of new approaches to therapy, and understanding of the disease. By sharing a patient perspective to this high-level research project we hope to play a role in identifying more effective treatments or strategies for managing the disease more effectively. We also hope to contribute to addressing unmet needs in IBD, in particular to finding solutions for challenges in IBD care, treatment, and quality of life.” Go to the METHYLOMIC website to see Luisa’s answers to the three questions:  https://lnkd.in/eZTsmTzx #METHYLOMIC #HORIZONEU #epigenetics #CrohnsDisease #RheumatoidArthritis #psoriasis #TargetingHope